PARP Inhibitor competition heating up and it won't be dominated by one player for ovarian or br
"The PARP inhibitor market is going to be split. The question is to what extent, and whether insurers, pharmacy benefit managers and...
CRI's Comprehensive Analysis of clinical immune-oncology
Cancer Research Institute publishes analysis in Annals of Oncology 2017 "Advances in immuno-oncology (IO) are revolutionizing the...
Oncology New Drug Approvals in 2017
Oncology Drugs Approved in 2017 thru Dec 8th Aliqopa (copanlisib); Bayer; For the treatment of follicular lymphoma , Approved September...
Rethinking the role of the Pharma Rep
In 1988, when I first managed a sales territory, the role of the representative was highly valued. A career as a pharmaceutical...
ASCO Report: National Survey Reveals Most Americans Are Unaware of Key Cancer Risk Factors
ASCO released its first annual National Cancer Opinion Survey this week. Survey reveals low awareness of key cancer risk factors among...
Cancer clinical trials in KS and MO: Bringing Hope to Patients
KC Business Journal Health Report Elise Reuter highlights the cancer clinical trials work ongoing in our local area....
ASCO: Disparities of Cancer
The National Cancer Institute defines cancer health disparities as “adverse differences in cancer incidence (new cases), cancer...
Speed to Market: Where is the evidence for EU oncology approvals?
Recent BMJ review looks at the data on oncology drugs approved in the EU from 2009-2013 to assess the overall survival and quality of...
Top 30 Oncology Products through 2016
Top 30 Oncology Drugs going into 2017...who will lead at year end? Click here to see more.
CAR-T cancer therapy is here: Here's how it works
A revolution in cancer therapy was approved by the FDA this week. Novartis' Kymriah (tisagenlecleucel), formerly known as CTL019, was...
